Antigenics Liabilities 2025

Antigenics Aktienanalyse

What does Antigenics do?

Antigenics Inc, now Agenus Inc, is a biotechnology company specializing in the research and development of innovative therapies for cancer and infectious diseases. The company is headquartered in Lexington, Massachusetts. The history of Antigenics begins in the late 1980s when the founder, Garo Armen, developed a method for identifying DNA sequences that encode specific proteins. The approach was based on the isolation of lentiviral vectors from human cells, which were then used to transfer the DNA sequences to other cells. This method allowed Antigenics to identify a variety of tumor-specific antigens (TSA) that could serve as potential targets for immunotherapies. In the 1990s, Antigenics focused on developing anti-tumor vaccines based on TSA. The first product was Oncophage, a vaccine made from individual TSA peptides isolated from the patient's tumor cells. Oncophage was tested in Phase II clinical trials in patients with various forms of cancer, including melanoma, renal cell carcinoma, and glioblastoma. Although the vaccine showed significant survival benefits in some studies, it was not approved in the United States. Today, Oncophage is used in Russia and India for the treatment of kidney cancer. In the late 2000s, Antigenics expanded its portfolio to include other immune-oncology approaches such as immune checkpoint protein CTLA-4 modulators, cytotoxic antibodies against cancer cells, and small molecules for immune activation. In 2014, the company was renamed Agenus Inc to reflect its expanded business model. Today, Agenus focuses on the development of immune combination therapies that combine various approaches to activate and modulate the immune system to achieve synergistic effects. The focus is on the use of immune checkpoint inhibitors that relieve T-cell inhibition, as well as the combination of vaccines and cytotoxic antibodies. Agenus' current products include immune checkpoint inhibitor CTLA-4 Ig, which is being tested in Phase III clinical trials for melanoma and lung cancer, and the QS-21 vaccine, which elicits a strong immune response and is used as an adjuvant for other vaccines for the treatment of infectious diseases. Agenus has various divisions, including a division for veterinary immunotherapies, which specializes in the development of vaccines and treatment methods for dogs and horses with cancer. Overall, Agenus has a rich history in the research and development of immunotherapies for the treatment of cancer and infectious diseases. Although the company has experienced setbacks in the past, it remains a key player in the field of immune-oncology and is expected to develop further groundbreaking therapies. Antigenics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Antigenics's Liabilities

Antigenics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Antigenics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Antigenics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Antigenics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Antigenics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Antigenics stock

What is the level of liabilities of Antigenics this year?

Antigenics has a debt balance of 0 USD this year.

What were the liabilities of Antigenics compared to the previous year?

The liabilities of Antigenics have increased by 0% dropped compared to the previous year.

What are the consequences of high debt for investors of Antigenics?

High liabilities can pose a risk for investors of Antigenics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Antigenics?

Low liabilities mean that Antigenics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Antigenics affect the company?

An increase in liabilities of Antigenics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Antigenics affect the company?

A decrease in the liabilities of Antigenics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Antigenics?

Some factors that can influence the liabilities of Antigenics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Antigenics so important for investors?

The liabilities of Antigenics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Antigenics take to modify the liabilities?

To change its liabilities, Antigenics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Antigenics pay?

Over the past 12 months, Antigenics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Antigenics is expected to pay a dividend of 0 USD.

What is the dividend yield of Antigenics?

The current dividend yield of Antigenics is .

When does Antigenics pay dividends?

Antigenics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Antigenics?

Antigenics paid dividends every year for the past 0 years.

What is the dividend of Antigenics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Antigenics located?

Antigenics is assigned to the '-' sector.

Wann musste ich die Aktien von Antigenics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Antigenics from 1/15/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/15/2025.

When did Antigenics pay the last dividend?

The last dividend was paid out on 1/15/2025.

What was the dividend of Antigenics in the year 2024?

In the year 2024, Antigenics distributed 0 USD as dividends.

In which currency does Antigenics pay out the dividend?

The dividends of Antigenics are distributed in USD.